Company intelligence / Profile preview

GNT Biotech & Medicals

Taipei, Taiwan

Ownership: Private
Employees: ~18
Development stage: Other

Overview

GNTbm develops oral cancer immunotherapy drugs targeting epigenetic regulation and immune activation. Lead program Kepida (Tucidinostat) is in clinical development for R/R PTCL and ER+/HER-2-negative breast cancer. Preclinical programs include GNTbm-38 (epigenetic immunoactivator) and GNTbm-TKI (novel multi-tyrosine kinase inhibitor with immune activation properties presented at 2025 ESMO Annual Meeting).

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

GNTBM-38

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Chipscreen Biosciences (licensed Kepida patent and market rights for Taiwan in September 2013)

Beyond the preview

Go deeper on GNT Biotech & Medicals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNT Biotech & Medicals.

Explore the full profile